SEC Company Response from 4D Molecular Therapeutics, (FDMT) — May 11, 2026
4D Molecular Therapeutics, Inc.
Date: May 11, 2026 · CIK: 0001650648 · Accession: 0001193125-26-216930
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-295650
Letter
Re: 4D Molecular Therapeutics, Inc. Registration Statement on Form S-3 (Registration No. 333-295650) To the addressee set forth above: In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-3 (Registration No. 333-295650) (the “ Registration Statement ”) of 4D Molecular Therapeutics, Inc. We respectfully request that the Registration Statement become effective as of 4:00 p.m., Washington, D.C. time, on May 13, 2026, or as soon as practicable thereafter, or at such other time thereafter as our counsel, Latham & Watkins LLP may request by telephone. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Latham & Watkins LLP, by calling Mark Roeder at (650) 463-3043 or John Williams at (415) 395-8223. Thank you for your assistance in this matter.
4D Molecular Therapeutics, Inc. 5858 Horton Street, #455 Emeryville, California 94608 May 11, 2026 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Lauren Hamill
Very truly yours,
4D M OLECULAR T HERAPEUTICS , I NC .
Show Raw Text
CORRESP 1 filename1.htm CORRESP 4D Molecular Therapeutics, Inc. 5858 Horton Street, #455 Emeryville, California 94608 May 11, 2026 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Lauren Hamill Re: 4D Molecular Therapeutics, Inc. Registration Statement on Form S-3 (Registration No. 333-295650) To the addressee set forth above: In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-3 (Registration No. 333-295650) (the “ Registration Statement ”) of 4D Molecular Therapeutics, Inc. We respectfully request that the Registration Statement become effective as of 4:00 p.m., Washington, D.C. time, on May 13, 2026, or as soon as practicable thereafter, or at such other time thereafter as our counsel, Latham & Watkins LLP may request by telephone. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Latham & Watkins LLP, by calling Mark Roeder at (650) 463-3043 or John Williams at (415) 395-8223. Thank you for your assistance in this matter. Very truly yours, 4D M OLECULAR T HERAPEUTICS , I NC . By: /s/ Kristian Humer Kristian Humer Chief Financial Officer cc: David Kirn, M.D., 4D Molecular Therapeutics, Inc. Scott Bizily, J.D., Ph.D., 4D Molecular Therapeutics, Inc. Mark V. Roeder, Latham & Watkins LLP John C. Williams, Latham & Watkins LLP